Severe hypertension in children and adolescents: Pathophysiology and treatment

Pediatric Nephrology

Volumn 24, Issue 6, 2009, Pages 1101-1112

  Flynn, Joseph T ^a,b   Tullus, Kjell ^c  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^b SEATTLE CHILDREN S RESEARCH INSTITUTE   (United States)

^c GREAT ORMOND STREET HOSPITAL   (United Kingdom)

Author keywords

Children; Clonidine; Esmolol; Hydralazine; Hypertension; Kidney disease; Labetalol; Nicardipine

Indexed keywords

ANGIOTENSIN I; ANGIOTENSIN II; CLEVIDIPINE; CLONIDINE; DIAZOXIDE; ENALAPRILAT; ESMOLOL; FENOLDOPAM; HYDRALAZINE; ISRADIPINE; LABETALOL; MINOXIDIL; NICARDIPINE; NITROPRUSSIDE SODIUM; URAPIDIL;

ACUTE KIDNEY FAILURE; ADOLESCENT; ADRENERGIC STIMULATION; AMBULATORY CARE; BLOOD PRESSURE REGULATION; BRADYCARDIA; BRONCHOSPASM; CHILD; CHRONIC DISEASE; CLINICAL PROTOCOL; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; CONTINUOUS INFUSION; DIFFERENTIAL DIAGNOSIS; DISEASE SEVERITY; DOSE TIME EFFECT RELATION; DROWSINESS; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; DRUG SAFETY; ECHOCARDIOGRAPHY; ECHOGRAPHY; ENDOTHELIAL DYSFUNCTION; FLUID RETENTION; GLOMERULOPATHY; HEART RATE; HEMOLYTIC UREMIC SYNDROME; HIRSUTISM; HOSPITAL CARE; HUMAN; HYPERTENSION; HYPOTENSION; INJECTION SITE PHLEBITIS; LOADING DRUG DOSE; MULTIPLE ORGAN FAILURE; NONHUMAN; OBSTRUCTIVE UROPATHY; OFF LABEL DRUG USE; OLIGURIA; PATHOPHYSIOLOGY; PHYSICAL EXAMINATION; PRIORITY JOURNAL; REBOUND; RECOMMENDED DRUG DOSE; REFLUX NEPHROPATHY; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; RENOVASCULAR DISEASE; REVIEW; SIDE EFFECT; SINGLE DRUG DOSE; SOMNOLENCE; TACHYCARDIA; THORAX RADIOGRAPHY; UNSPECIFIED SIDE EFFECT; XEROSTOMIA;

ADOLESCENT; ALGORITHMS; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; CHILD; CHILD, PRESCHOOL; CLINICAL TRIALS AS TOPIC; HUMANS; HYPERTENSION; SEVERITY OF ILLNESS INDEX;

EID: 67650293226     PISSN: 0931041X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00467-008-1000-1     Document Type: Review

References (60)

1. National High Blood Pressure Education Program Working Group on High Blood Pressure in Children and Adolescents (2005) The Fourth report on the diagnosis, evaluation, and treatment of high blood pressure in children and adolescents. National Institute of Health publication 05:5267. Bethesda, MD, National Heart, Lung, and Blood Institute
2. Marik PE, Varon J (2007) Hypertensive crises: Challenges and management. Chest 131:1949-1962
3. Haas CE, LeBlanc JM (2004) Acute postoperative hypertension: A review of therapeutic options. Am J Health Syst Pharm 61:1661-1673
4. Flynn JT (2005) Hypertension in childhood and adolescence. In: Kaplan NM (ed) Kaplan's clinical hypertension, 9th edn. Lippincott-Williams and Wilkins, Philadelphia, pp 465-488
5. Deal JE, Barratt TM, Dillon MJ (1992) Management of hypertensive emergencies. Arch Dis Child 67:1089-1092
6. Flynn JT, Mottes TA, Brophy PB, Kershaw DB, Smoyer WE, Bunchman TE (2001) Intravenous nicardipine for treatment of severe hypertension in children. J Pediatr 139:38-43
7. Bender SR, Fong MW, Heitz S, Bisognano JD (2006) Characteristics and management of patients presenting to the emergency department with hypertensive urgency. J Clin Hypertens 8:12-18
8. Rose JC, Mayer SA (2004) Optimizing blood pressure in neurological emergencies. Neurocrit Care 1:287-299
9. Shroff R, Roebuck DJ, Gordon I, Davies R, Stephens S, Marks S, Chan M, Barkovics M, McLaren CA, Shah V, Dillon MJ, Tullus K (2006) Angioplasty for renovascular hypertension in children: 20-year experience. Pediatrics 118:268-275
10. Vaughan CJ, Delanty N (2000) Hypertensive emergencies. Lancet 356:411-417
11. Schwartz RB, Jones KM, Kalina P, Bajakian RL, Mantello MT, Garada B, Holman BL (1992) Hypertensive encephalopathy: Findings on CT, MR imaging, and SPECT imaging in 14 cases. AJR Am J Roentgenol 159:379-383
12. Flynn JT, Woroniecki RP (2003) Pathophysiology of hypertension. In: Avner E, Harmon W, Niaudet P (eds) Pediatric nephrology, 5th edn. Lippincott Williams and Wilkins, Philadelphia, pp 1153-1178
13. Funakoshi Y, Ichiki T, Ito K, Takeshita A (1999) Induction of interleukin-6 expression by angiotensin II in rat vascular smooth vascular cells. Hypertension 34:118-125
14. Mullins JJ, Peters J, Ganten D (1990) Fulminant hypertension in transgenic rats harboring the mouse Ren-2 gene. Nature 344:541-544
15. Montgomery HE, Kiernan LA, Whitworth CE, Fleming S, Unger T, Gohlke P, Mullins JJ, McEwan JR (1998) Inhibition of tissue angiotensin converting enzyme activity prevents malignant hypertension in TGR(mREN2)27. J Hypertens 16:635-643
16. Padfield PL, Brown JJ, Lever AF, Morton JJ, Robertson JI (1981) Blood pressure in acute and chronic vasopressin excess: Studies of malignant hypertension and the syndrome of inappropriate antidiuretic hormone secretion. N Engl J Med 304:1067-1070
17. Brouwers FM, Eisenhofer G, Lenders JW, Pacak K (2006) Emergencies caused by pheochromocytoma, neuroblastoma, or ganglioneuroma. Endocrinol Metab Clin North Am 35:699-724
18. Rauth W, Hund E, Sohl G, Rascher W, Mehls O, Scharer K (1983) Vasoactive hormones in children with chronic renal failure. Kidney Int Suppl 15:S27-S33
19. Faber JE, Brody MA (1985) Afferent renal nerve-dependent hypertension following acute renal artery stenosis in the conscious rat. Circ Res 57:676-688
20. Whitworth CE, Veniant MM, Firth JD, Cumming AD, Mullins JJ (1995) Endothelin in the kidney in malignant phase hypertension. Hypertension 26:925-931
21. Vaziri ND, Ni Z, Wang XQ, Oveisi F, Zhou XJ (1998) Downregulation of nitric oxide synthase in chronic renal insufficiency: Role of excess PTH. Am J Physiol 274:F642-F649
22. Endemann DH, Schiffrin EL (2004) Endothelial dysfunction. J Am Soc Nephrol 15:1983-1992
23. Patel H, Mitsnefes M (2005) Advances in the pathogenesis and management of hypertensive crisis. Curr Opin Pediatr 17:210-214
24. Muller DN, Dechend R, Mervaala EMA, Park J-K, Schmidt F, Fiebler A, Theuer J, Ganten D, Haller H, Luft FC (2000) NF-κB inhibition ameliorates angotensin II induce inflammatory damage in rats. Hypertension 35:193-201
25. Lip GYH, Edmunds E, Hee FL, Blann AD, Beevers DG (2001) A cross-sectional, diurnal, and follow-up study of platelet activation and endothelial dysfunction in malignant phase hypertension. Am J Hypertens 14:627-631
26. Seeman T (2007) Hypertension after renal transplantation. Pediatr Nephrol doi: 10.1007/s00467-007-0627-7
27. Grossman E, Messerli FH (2008) Secondary hypertension: Interfering substances. J Clin Hypertens (Greenwich) 10:556-566
28. U.S. Food and Drug Administration. Summaries of medical and clinical pharmacology reviews of pediatric studies. Available at: http://www.fda.gov/cder/pediatric/Summaryreview.htm. Accessed 3 June 2008
29. Treluyer JM, Hubert P, Jouvet P, Couderc S, Cloup M (1993) Intravenous nicardipine in hypertensive children. Eur J Pediatr 152:712-714
30. Michael J, Groshong T, Tobias JD (1998) Nicardipine for hypertensive emergencies in children with renal disease. Pediatr Nephrol 12:40-42
31. Tenney F, Sakarcan A (2000) Nicardipine is a safe and effective agent in pediatric hypertensive emergencies. Am J Kidney Dis 35:E20
32. Nakagawa TA, Sartori SC, Morris A, Schneider DS (2004) Intravenous nicardipine for treatment of postcoarctectomy hypertension in children. Pediatr Cardiol 25:26-30
33. Flynn JT (2003) Successes and shortcomings of the FDA Modernization Act. Am J Hypertens 16:889-891
34. Dunne J (2007) The European Regulation on medicines for paediatric use. Paediatr Respir Rev 8:177-183
35. Public law 107-109. Best Pharmaceuticals for Children Act. Enacted January 4, 2002. Available at: http://www.fda.gov/opacom/laws/pharmkids/ contents.html. Accessed 3 June 2008
36. Rocco TP, Fang JC (2006) Pharmacotherapy of congestive heart failure. In: Brunton LL, Lazo JS, Parker KL (eds) Goodman & Gilman's the pharmacological basis of therapeutics, 11th edn. McGraw-Hill, New York, pp 869-898
37. Goa KL, Benfield P, Sorkin EM (1989) Labetalol. A reappraisal of its pharmacology, pharmacokinetics and therapeutic use in hypertension and ischaemic heart disease. Drugs 37:583-627
38. Bunchman TE, Lynch RE, Wood EG (1992) Intravenously administered labetalol for treatment of hypertension in children. J Pediatr 120:140-144
39. Flynn JT, Pasko DA (2000) Calcium channel blockers: Pharmacology and place in therapy of pediatric hypertension. Pediatr Nephrol 15:302-316
40. Wallin JD, Bienvenu GS, Cook E, Laddu A, Turlapaty P, Clifton GG (1990) Nicardipine in severe hypertension: Oral therapy following intravenous treatment. Int J Clin Pharmacol Ther Toxicol 28:14-19
41. Hoffman BB (2006) Therapy of hypertension. In: Brunton LL, Lazo JS, Parker KL (eds) Goodman & Gilman's the pharmacological basis of therapeutics, 11th edn. McGraw-Hill, New York, pp 845-868
42. Alexander KS, Pudipeddi M, Parker GA (1993) Stability of hydralazine hydrochloride syrup compounded from tablets. Am J Hosp Pharm 50:683-686
43. Kirsten R, Nelson K, Kirsten D, Heintz B (1998) Clinical pharmacokinetics of vasodilators. Part I. Clin Pharmacokinet 34:457-482
44. McCrory WW, Kohaut EC, Lewy JE, Lieberman E, Travis LB (1979) Safety of intravenous diazoxide in children with severe hypertension. Clin Pediatr 18:661-667, 671
45. Grossman E, Ironi AN, Messerli FH (1998) Comparative tolerability profile of hypertensive crisis treatments. Drug Saf 19:99-122
46. Adamson PC, Rhodes LA, Saul JP, Dick M 2nd, Epstein MR, Moate P, Boston R, Schreiner MS (2006) The pharmacokinetics of esmolol in pediatric subjects with supraventricular arrhythmias. Pediatr Cardiol 27:420-427
47. Wells TG, Bunchman TE, Kearns GL (1990) Treatment of neonatal hypertension with enalaprilat. J Pediatr 117:664-667
48. Sica DA (2007) Centrally acting antihypertensive agents: An update. J Clin Hypertens (Greenwich) 9:399-405
49. Falkner B, Onesti G, Lowenthal DT, Affrime MB (1983) The use of clonidine monotherapy in adolescent hypertension. Chest 83(Suppl 2):425-427
50. MacDonald JL, Johnson CE, Jacobson P (1994) Stability of isradipine in an extemporaneously compounded oral liquid. Am J Hosp Pharm 51:2409-2411
51. Strauser LM, Groshong T, Tobias JD (2000) Initial experience with isradipine for the treatment of hypertension in children. South Med J 93:287-293
52. Flynn JT, Warnick SJ (2002) Isradipine treatment of hypertension in children: A single-center experience. Pediatr Nephrol 17:748-753
53. Saragoça MA, Portela JE, Plavnik F, Ventura RP, Lotaif L, Ramos OL (1992) Isradipine in the treatment of hypertensive crisis in ambulatory patients. J Cardiovasc Pharmacol 19(Suppl 3):S76-S78
54. Pennisi AJ, Takahashi M, Bernstein BH, Singsen BH, Uittenbogaart C, Ettenger RB, Malekzadeh MH, Hanson V, Fine RN (1977) Minoxidil therapy in children with severe hypertension. J Pediatr 90:813-819
55. Strife CF, Quinlan M, Waldo FB, Fryer CJ, Jackson EC, Welch TR, McEnery PT, West CD (1986) Minoxidil for control of acute blood pressure elevation in chronically hypertensive children. Pediatrics 78:861-865
56. Murphy MB, Murray C, Shorten GD (2001) Fenoldopam - a selective peripheral dopamine-receptor agonist for the treatment of severe hypertension. N Engl J Med 345:1548-1557
57. Nordlander M, Sjöquist P-O, Ericsson H, Rydén L (2004) Pharmacodynamic, pharmacokinetic and clinical effects of clevidipine, an ultrashort-acting calcium antagonist for rapid blood pressure control. Cardiovasc Drug Rev 22:227-250
58. Powroznyk AVV, Vuylsteke A, Naughton C, Misso SL, Holloway J, Jolin-Mellgård Å, Latimer RD, Nordlander M, Feneck RO (2003) Comparison of clevidipine with sodium nitroprusside in the control of blood pressure after coronary artery surgery. Eur J Anaesthesiol 20:697-703
59. Dooley M, Goa KL (1998) Urapidil. A reappraisal of its use in the management of hypertension. Drugs 56:929-955
60. Woisetschläger C, Bur A, Vlcek M, Derhaschnig U, Laggner AN, Hirschl MM (2006) Comparison of intravenous urapidil and oral captopril in patients with hypertensive urgencies. J Hum Hypertens 20:707-709